Breast Cancer Now media statements
We support latest Emmerdale storyline on Faith Dingle's Secondary Breast Cancer diagnosis
Catherine Priestley, Clinical Nurse Specialist at Breast Cancer Now, said:
We comment on saliva samples used to determine breast cancer risk in women of screening age
We have commented on new research published in Genetics in Medicine titled 'Breast cancer risk stratification in women of screening age: Inc...
We welcome NICE approval of pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We comment on new research which shows the drug trastuzumab deruxtecan may benefit even more breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to new findings from the Lumina trial which suggest some patients could avoid radiotherapy
Breast Cancer Now has commented on findings from the Lumina trial presented at the American Society of Clinical Oncology (ASCO).
We respond to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021
In response to today’s Royal College of Radiologists’ clinical radiology and clinical oncology censuses, Baroness Delyth Morgan, Chief Execu...
We respond to research that suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes
In response to research published in Genome Medicine, and part-funded by Breast Cancer Now, which suggests drugs that neutralise progesteron...
We respond to the approval of breast cancer drug abemaciclib for routine use on the NHS
In response to the news abemaciclib has been approved by THE National Institute for Health and Care Excellence (NICE) for routine use on the...
Breast Cancer Now celebrates landmark victory as Trodelvy is recommended for use on the NHS in England
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Breast Cancer Now welcomes NICE decision to recommend alpelisib with fulvestrant for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to MP Dawn Butler's mission to find the Million Missing Mammograms
Following MP Dawn Butler's appearance on This Morning today, announcing her mission to find the Million Missing Mammograms, Breast Cancer No...
We respond to Macmillan Cancer Support's warning that "almost 50,000 people are still missing a cancer diagnosis in the UK"
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said: